Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
LUNG Stock Chart & Stats
$1.98
-$0.17(-2.57%)
At close: 4:00 PM EST
$1.98
-$0.17(-2.57%)
Day’s Range― - ―
52-Week Range$1.47 - $9.37
Previous CloseN/A
Volume95.69K
Average Volume (3M)308.20K
Market Cap
$66.82M
Enterprise Value$77.06M
Total Cash (Recent Filing)$84.22M
Total Debt (Recent Filing)$56.83M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 12, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding40,746,555
10 Day Avg. Volume245,979
30 Day Avg. Volume308,202
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)3.09
Price to Sales (P/S)3.17
P/FCF Ratio-8.05
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue0.85
Enterprise Value/Gross Profit1.16
Enterprise Value/Ebitda-1.28
Forecast
1Y Price Target
$4.10Price Target Upside107.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial PerformancePulmonx announced preliminary Q3 revenue of $21.5M, which exceeded both the analyst's estimate and the consensus, indicating strong financial performance.
Growth StrategyThe new management team is expected to outline a strategy to return Pulmonx to a high-growth company, which is viewed positively by analysts.
Management StabilityThe original management team of Pulmonx Corporation, including former CEO Glen French and former CFO Derrick Sung, has returned to their roles, which is seen as a stabilizing move for the company.
Bears Say
Financing ConcernsThere is a worry that Pulmonx Corporation may need to secure financing in the next year or two that is unfavorable to equity holders.
Revenue Growth ConcernsThe guidance revision for FY25 implies revenue growth taking longer than anticipated to translate into actual results.
U.S. Market DecelerationThe high-margin U.S. business is decelerating for a sixth consecutive quarter, and underlying trends are shifting, leading to a downgrade to Neutral.
Pulmonx News
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $1.47 and its highest was $9.37 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is $66.82M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Nov 12, 2025 which is in 13 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Jul 30, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.394 by $0.014.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.42.
How many shares outstanding does Pulmonx have?
Pulmonx has 40,746,555 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.394. Following the earnings report the stock price went down -41.587%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in LUNG
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.10 (107.07% Upside)
$4.10 (107.07% Upside)
Hedge Fund Trend
Decreased
By 232.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.30%
12-Months-Change
Fundamentals
Return on Equity
-66.88%
Trailing 12-Months
Asset Growth
-14.74%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
LUNG Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong international revenue growth and significant progress in expanding screening and treatment capacity. However, these positives were offset by the downward revision of revenue guidance, decline in gross margins, and slower than expected U.S. revenue growth due to capacity constraints and evolving priorities. The overall sentiment reflects a balanced view with positive international performance but challenges in U.S. market execution.View all LUNG earnings summariesLUNG Stock 12 Month Forecast
Average Price Target
$4.10
▲(107.07% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Ownership Overview
6.86% Insiders
30.76% Mutual Funds
0.07% Other Institutional Investors
46.82% Public Companies and
Individual Investors